Sanofi, Translate Bio Start Phase 1/2 Clinical Trial of Covid-19 Vaccine Candidate
March 12 2021 - 2:01AM
Dow Jones News
By Kim Richters
Sanofi and Translate Bio Inc. are starting the Phase 1/2
clinical trial of their mRNA Covid-19 vaccine candidate, the
companies said Friday.
The clinical trial--expected with 415 participants--will assess
safety, immune response and reactogenicity, and interim results are
expected in the third quarter, Sanofi and Translate said.
Preclinical data for the candidate vaccine MRT5500 had
demonstrated high neutralizing antibody levels, they said.
Sanofi and Translate said they are also working on improving the
vaccine's temperature stability.
At the same time, pre-clinical studies are continuing to assess
MRT5500 and additional mRNA vaccine candidates against SARS-CoV-2
variants, the companies said.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
March 12, 2021 01:46 ET (06:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From May 2023 to May 2024
